Stereoselective Synthesis of Novel Aristeromycin Analogues as Potential Antiviral Agents

Abstract

A series of 3′-methyl-branched and purine-modified analogues of aristeromycin were synthesized via the SN₂ displacement of a key triflate, which was prepared from a readily available enantiopure building block in eight steps. The synthesized compounds were evaluated as potential antiviral agents against important viruses. Only the 2,6-diaminopurine derivative exhibited moderate activity against vesicular stomatitis virus.

Key words

synthesis - carbanucleosides - nucleobases - S_N2 displacement - antiviral activity

References

• 1 Kishi T. Muroi M. Kusaka T. Nishikawa M. Kamiya K. Mizuno K. J. Chem. Soc., Chem. Commun.  1967,  852 
• 2 Kusaka T. Yamamoto H. Shibata M. Muroi M. Kishi T. Mizuko K. J. Antibiot.  1968,  21:  255 
• 3 Kishi T. Muroi M. Kusaka T. Nishikawa M. Kamiya K. Mizuno K. Chem. Pharm. Bull.  1972,  20:  940 
• 4 Ueland PM. Pharmacol. Rev.  1982,  34:  223 
• 5 De Clercq E. Biochem. Pharmacol.  1987,  36:  2567 
• 6 Cools M. De Clercq E. Biochem. Pharmacol.  1989,  38:  1061 
• 7 De Clercq E. Nucleosides Nucleotides  1998,  17:  625 
• 8 De Clerq E. Nucleosides, Nucleotides Nucleic Acids  2005,  24:  1395 
• 9 Cantoni GL. In Biological Methylation and Drug Design   Borchardt RT. Creveling CR. Ueland PM. Humana Press; Clifton NJ: 1986.  p.227-238  
• 10 Turner MA. Yang XD. Kuczera K. Borchardt RT. Howell PL. Cell Biochem. Biophys.  2000,  33:  101 
• 11 Bennet LL. Brockman RW. Rose LM. Allan PW. Shaddix SC. Shealy YF. Clayton JD. Mol. Pharmacol.  1985,  27:  666 
• 12 Wolfe MS. Borchardt RT. J. Med. Chem.  1991,  34:  1521 
• 13 2′-Methylaristeromycin: Gosselin G. Griffe L. Meillon J.-C. Storer R. Tetrahedron  2006,  62:  906 
• 4′-Methylaristeromycin:
• 14a Wachtmeister J. Mühlman A. Classon B. Samuelsson B. Tetrahedron  1999,  55:  10761 
• 14b Gumina G. Chong Y. Choi Y. Chu CK. Org. Lett.  2000,  2:  1229 
• 14c Yin X.-q. Schneller SW. Tetrahedron Lett.  2006,  47:  4057 
• 15 5′-Methylaristeromycin: Ye W. Schneller SW. J. Org. Chem.  2006,  71:  8641 
• 16 Franchetti P. Cappellacci L. Pasqualini M. Petrelli R. Vita P. Jayaram HN. Horvath Z. Szekerers T. Grifantini M. J. Med. Chem.  2005,  48:  4983 
• 17 Brémond P. Audran G. Aubin Y. Monti H. Synlett  2007,  1124 
• 18 Marquez VE. In Advances in Antiviral Drug Design   Vol. 2:  De Clercq E. JAI Press Inc.; Connecticut: 1996.  p.89-146  
• 19 Anti-HIV Nucleosides: Past, Present and Future   Mitsuya H. R. G. Landes Co; Georgetown TX: 1997. 
• 20 Kitade Y. Kozaki A. Miwa T. Nakanishi M. Tetrahedron  2002,  58:  1271 
• 21 Audran G. Acherar S. Monti H. Eur. J. Org. Chem.  2003,  92 
• 22 Corey EJ. Venkateswarlu A. J. Am. Chem. Soc.  1972,  94:  6190 
• 23a Mitsunobu O. Synthesis  1981,  1 
• 23b Jenny TF. Horlacher J. Previsani N. Benner SA. Helv. Chim. Acta  1992,  75:  1944 
• Review:
• 23c Hughes DL. Org. Prep. Proced. Int.  1996,  28:  127 
• 23d But TYS. Toy PH. Chem. Asian J.  2007,  2:  1340 
• 24 Griffith WP. Ley SV. Aldrichimica Acta  1990,  23:  13 
• 25a Kazimierczuk Z. Revankar GR. Robins RK. Nucleic Acids Res.  1984,  12:  1179 
• 25b Kazimierczuk Z. Cottam HB. Revankar GR. Robins RK. J. Am. Chem. Soc.  1984,  106:  6379 
• 26a Pathak T. Bazin H. Chattopadhyaya J. Tetrahedron  1986,  42:  5427 
• 26b Johnston TP. Holum LB. Montgomery JA. J. Am. Chem. Soc.  1958,  80:  665 
• 27 De Clercq E. In Vivo and Ex Vivo Text Systems to Rationalize Drug Design and Delivery   Cromelin D. Couvreur P. Duchene D. Editions de Santé; Paris: 1994. 
• 28 Sheldrick GM. SHELXL-97, Program for Crystal Structure Refinement   University of Göttingen; Germany: 1997. 

29

CCDC-689835 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: [phone]; E-mail: [e-mail].